江濤 廖英堅(jiān)

[摘要]目的 探討前列地爾治療冠狀動(dòng)脈粥樣硬化性心臟病患者的臨床效果。方法 選取2016年10月～2018年10月我院收治的50例冠狀動(dòng)脈粥樣硬化性心臟病患者作為研究對(duì)象，按照隨機(jī)數(shù)字表法分為觀察組（25例）和對(duì)照組（25例）。觀察組采用前列地爾治療，對(duì)照組采用硝酸甘油治療。比較兩組的臨床治療效果、心功能相關(guān)指標(biāo)及治療前后的血脂水平。結(jié)果 觀察組的治療總有效率高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組的每搏心輸出量（SV）高于對(duì)照組，心率（HR）低于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療前，兩組的血清總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白膽固醇（LDL-C）及高密度脂蛋白膽固醇（HDL-C）水平比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）;治療后，兩組的TC、TG、LDL-C水平低于治療前，HDL-C水平高于治療前，觀察組的TC、TG、LDL-C水平低于對(duì)照組，HDL-C水平高于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 對(duì)冠狀動(dòng)脈粥樣硬化性心臟病患者采用前列地爾治療，能提高治療效果，改善心功能指標(biāo)及血脂水平，值得臨床推廣應(yīng)用。

[關(guān)鍵詞]前列地爾;冠狀動(dòng)脈粥樣硬化性心臟病;臨床效果;心功能

[中圖分類號(hào)] R714.252? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-4721（2020）2（c）-0076-03

Clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease

JIANG Tao? ?LIAO Ying-jian

Department of Cardiovascular Medicine， the Second People′s Hospital of Pingxiang City， Jiangxi Province， Pingxiang? ?337000， China

[Abstract] Objective To explore the clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease. Methods Fifty patients with coronary atherosclerotic heart disease treated in our hospital from October 2016 to October 2018 were selected as the research subjects， they were divided into the observation group （25 cases） and the control group （25 cases） according to the random number table method. The observation group was treated with Alprostadil， the control group was treated with Nitroglycerin. The clinical treatment effects， cardiac function-related indicators， and blood lipid levels before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group， the difference was statistically significant （P<0.05）. The cardiac output （SV） of the observation group was higher than that of the control group，? the heart rate （HR） was lower than that of the control group， the differences were statistically significant （P<0.05）. Before treatment， there were no significant differences in serum total cholesterol （TC）， triacylglycerol （TG）， low density lipoprotein cholesterol （LDL-C）， and high density lipoprotein cholesterol （HDL-C） between the two groups （P>0.05）. After treatment， the levels of TC， TG， and LDL-C in the two groups were lower than those of before treatment， the levels of HDL-C was higher than that of before treatment， the levels of TC， TG， LDL-C in the observation group were lower than those in the control group， the levels of HDL-C was higher than that in the control group， the differences were statistically significant （P<0.05）. Conclusion The use of Alprostadil in patients with coronary atherosclerotic heart disease can improve the treatment effect， improve cardiac function indicators and blood lipid levels， which is worthy of clinical application.